Drug Trial Radar · NCT01093729
A Study of HM11260C in Healthy Male Subject
Last checked: Nov 19, 2026Latest source record: Feb 7, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
41
Actual
Start
Feb 2010
Primary completion
Oct 2010
Study completion Oct 2010
Sponsor
- Lead sponsor
- Hanmi Pharmaceutical Company LimitedIndustry
- Sponsor type
- Industry
- First posted
- Mar 26, 2010
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Single group
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- Male only, from 20 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Study Design: Randomized, double-blind, placebo-controlled, escalating single-dose design. Five ascending dose cohorts are planned.
Conditions
- Healthy
Interventions
HM11260CDrug
HM11260C 0.5mcg/kg or Placebo
HM11260CDrug
HM11260C 2mcg/kg or Placebo
HM11260CDrug
HM11260C 4mcg/kg or Placebo
HM11260CDrug
HM11260C 8mcg/kg or Placebo
HM11260CDrug
HM11260C 14mcg/kg or Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- SafetyTime frame: 1, 2, 3, 4, 5, 7, 9, 16, 22, 30, 36, 43, 57, 84 Day
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.